Kexing Biopharm Management

Management criteria checks 3/4

Kexing Biopharm's CEO is Yanqing Zhao, appointed in Jul 2019, has a tenure of 5.33 years. directly owns 0.039% of the company’s shares, worth CN¥1.26M. The average tenure of the management team and the board of directors is 5.3 years and 5.3 years respectively.

Key information

Yanqing Zhao

Chief executive officer

CN¥1.1m

Total compensation

CEO salary percentage	n/a
CEO tenure	5.3yrs
CEO ownership	0.04%
Management average tenure	5.3yrs
Board average tenure	5.3yrs

Recent management updates

Recent updates

There's No Escaping Kexing Biopharm Co., Ltd.'s (SHSE:688136) Muted Revenues Despite A 36% Share Price Rise

Oct 08

Kexing Biopharm Co., Ltd.'s (SHSE:688136) Share Price Boosted 36% But Its Business Prospects Need A Lift Too

May 21

Shandong Kexing Bioproducts Co,.Ltd (SHSE:688136) Held Back By Insufficient Growth Even After Shares Climb 25%

Mar 08

CEO

Yanqing Zhao (42 yo)

5.3yrs

Tenure

CN¥1,070,600

Compensation

Mr. Yanqing Zhao is MD & Director of Kexing Biopharm Co. Ltd. from July 29, 2019.

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Yanqing Zhao	MD & Director	5.3yrs	CN¥1.07m	0.039% CN¥ 1.3m
Xiaoqin Wang	Head of Accounting	5.3yrs	CN¥742.40k	0.020% CN¥ 647.6k
Ning Cui	Deputy GM & Director	5.3yrs	CN¥692.50k	0.016% CN¥ 531.3k
Suofu Qin	Deputy General Manager	no data	CN¥1.30m	0.023% CN¥ 745.3k
Ke Shao	Deputy General Manager	no data	CN¥1.80m	0.041% CN¥ 1.3m
Hongjie Ma	Deputy General Manager	5.3yrs	CN¥844.10k	0.018% CN¥ 574.4k

5.3yrs

Average Tenure

50yo

Average Age

Experienced Management: 688136's management team is seasoned and experienced (5.3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Yanqing Zhao	MD & Director	5.3yrs	CN¥1.07m	0.039% CN¥ 1.3m
Ning Cui	Deputy GM & Director	5.3yrs	CN¥692.50k	0.016% CN¥ 531.3k
An Tang	Independent Director	5.3yrs	CN¥180.00k	no data
Xueqin Deng	Chairman of the Board	5.3yrs	no data	0.89% CN¥ 29.2m
Jianhong Tao	Independent Director	5.3yrs	CN¥180.00k	no data
Die Li	Employee Representative Supervisor	2.3yrs	no data	no data
Wei Liu	Supervisor	1.3yrs	no data	no data

5.3yrs

Average Tenure

47yo

Average Age

Experienced Board: 688136's board of directors are considered experienced (5.3 years average tenure).

Kexing Biopharm Management

Management criteria checks 3/4

Key information

Recent management updates

Kexing Biopharm Co., Ltd., Annual General Meeting, May 24, 2024

Kexing Biopharm Co., Ltd., Annual General Meeting, May 24, 2024

Less than half of directors are independent

Insufficient new directors

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.03 (vs CN¥0.042 loss in 3Q 2023)

There's No Escaping Kexing Biopharm Co., Ltd.'s (SHSE:688136) Muted Revenues Despite A 36% Share Price Rise

Kexing Biopharm Co., Ltd. to Report Q3, 2024 Results on Oct 26, 2024

Second quarter 2024 earnings released: CN¥0.003 loss per share (vs CN¥0.22 loss in 2Q 2023)

Kexing Biopharm Co., Ltd. to Report First Half, 2024 Results on Aug 24, 2024

Kexing Biopharm Co., Ltd. Announces Its Subsidiary Shenzhen Kexing Pharmaceutical Co., Ltd., Obtains Clinical Trial Approval for its Self-Developed Class I Innovative Drug--Long-Acting Growth Hormone

Kexing Biopharm Co., Ltd.'s (SHSE:688136) Share Price Boosted 36% But Its Business Prospects Need A Lift Too

Kexing Biopharm Co., Ltd., Annual General Meeting, May 24, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Kexing Biopharm Co., Ltd., Annual General Meeting, May 24, 2024

Shenzhen Kexing Pharmaceutical Co., Ltd. Announces Enrollment of Subjects in Phase III Clinical Trial for Inhaled Aerosol Drug in Children by Kexing Biopharm

Shandong Kexing Bioproducts Co,.Ltd to Report Q1, 2024 Results on Apr 27, 2024

Shandong Kexing Bioproducts Co,.Ltd (SHSE:688136) Held Back By Insufficient Growth Even After Shares Climb 25%

Less than half of directors are independent

Shandong Kexing Bioproducts Co,.Ltd (SHSE:688136) announces an Equity Buyback for CNY 60 million worth of its shares.

New minor risk - Share price stability

Third quarter 2023 earnings released: CN¥0.033 loss per share (vs CN¥0.23 loss in 3Q 2022)

Second quarter 2023 earnings released: CN¥0.22 loss per share (vs CN¥0.13 loss in 2Q 2022)

Shandong Kexing Bioproducts Co,.Ltd announced that it expects to receive CNY 571.6 million in funding

Shandong Kexing Bioproducts Co,.Ltd to Report First Half, 2023 Results on Aug 26, 2023

First quarter 2023 earnings released: CN¥0.04 loss per share (vs CN¥0.15 profit in 1Q 2022)

Full year 2022 earnings released: CN¥0.45 loss per share (vs CN¥0.49 profit in FY 2021)

Insufficient new directors

Third quarter 2022 earnings released: CN¥8.24 loss per share (vs CN¥0.072 profit in 3Q 2021)

Second quarter 2022 earnings released: CN¥0.068 loss per share (vs CN¥0.075 profit in 2Q 2021)

First quarter 2022 earnings released: EPS: CN¥0.15 (vs CN¥0.23 in 1Q 2021)

Full year 2021 earnings released: EPS: CN¥0.49 (vs CN¥0.93 in FY 2020)

Investor sentiment improved over the past week

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.072 (vs CN¥0.16 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.075 (vs CN¥0.16 in 2Q 2020)

Investor sentiment improved over the past week

Full year 2020 earnings released: EPS CN¥0.93 (vs CN¥1.07 in FY 2019)

Shan Dong Kexing Bioproducts Co., Ltd has completed an IPO in the amount of CNY 1.109249 billion.

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age